Applying real world evidence to clinical trials with Cristina Chang

In the final episode of season 1, Sylvain Berthelot welcomes Dr. Cristina Chang, Chief Medical Officer at HiRO, to unpack the growing importance of real-world evidence (RWE) in clinical development.

With decades of experience across global pharmaceutical companies, Cristina shares her deep insights into how real-world data is being applied to clinical trials to enhance patient outcomes, regulatory submissions, and post-marketing strategies. She discusses the practical considerations for using RWE, from data collection challenges to ensuring scientific rigor, as well as how the regulatory landscape is evolving to support these efforts.

Cristina also reflects on cultural and organizational changes needed to integrate RWE into clinical development successfully, and how emerging technologies and cross-functional collaboration can drive this transformation.

Join us as we explore how real-world evidence is shifting from a buzzword to a critical component of evidence generation in modern clinical research.

Share via

See CRScube in action

Book a demo

Explore how our platform will elevate your team and clinical trial management.

Get insights straight to your inbox

Explore our knowledge base

Stay in-the-know with regular updates and industry opinions from our expert team.

See all resources

Featured resources

Modern safety reporting in a legacy world – How cubeSAFETY compares, according to CRScube’s COO

Safety reporting is moving beyond simple adverse event collection. The future lies in intelligent risk detection and frictionless data capture.

Electronic safety reporting in clinical trials: What sponsors need to know

For sponsors and CROs, it is crucial to understand the implications of the full enforcement of ICH E2B(R3) standards, especially as it impacts both pre- and post-authorization submissions.